Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 2/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4383823 | 0.86 | GBA1 (0.46) | MEN1KMT2ACYP2C9LIPEGBA1 | |
| SCHEMBL4381986 | 0.85 | MEN1 (0.49) | MEN1KMT2ACYP2C9LIPEGBA1 | |
| SCHEMBL4390246 | 0.84 | MEN1 (0.41) | MEN1KMT2ACYP2C9LIPEGBA1 | |
| SCHEMBL4388852 | 0.83 | MEN1 (0.41) | MEN1KMT2ACYP2C9LIPEGBA1 | |
| SCHEMBL4386048 | 0.83 | MEN1 (0.41) | MEN1KMT2ACYP2C9LIPEGBA1 | |
| SCHEMBL4386428 | 0.83 | PRCP (0.46) | MEN1KMT2ACYP2C9LIPEGBA1 | |
| SCHEMBL4380572 | 0.82 | MEN1 (0.43) | MEN1KMT2ACYP2C9LIPEGBA1 | |
| SCHEMBL4379574 | 0.82 | MAPT (0.46) | MEN1KMT2ACYP2C9GBA1ALDH1A1 | |
| SCHEMBL4384497 | 0.81 | MEN1 (0.43) | MEN1KMT2ACYP2C9LIPEEPHX2 | |
| SCHEMBL4385279 | 0.81 | HSD11B1 (0.44) | MEN1KMT2ACYP2C9GBA1PRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | MEN1 3694/4885KMT2A 2079/4885CYP2C9 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.